

# Overactive Bladder Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/O1D79C7A01AMEN.html>

Date: March 2018

Pages: 153

Price: US\$ 3,680.00 (Single User License)

ID: O1D79C7A01AMEN

## Abstracts

### Report Summary

Overactive Bladder Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Overactive Bladder Drug industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Overactive Bladder Drug 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Overactive Bladder Drug worldwide and market share by regions, with company and product introduction, position in the Overactive Bladder Drug market

Market status and development trend of Overactive Bladder Drug by types and applications

Cost and profit status of Overactive Bladder Drug, and marketing status

Market growth drivers and challenges

The report segments the global Overactive Bladder Drug market as:

Global Overactive Bladder Drug Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)  
Middle East and Africa

Global Overactive Bladder Drug Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

Global Overactive Bladder Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Global Overactive Bladder Drug Market: Manufacturers Segment Analysis (Company and Product introduction, Overactive Bladder Drug Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (U.S.)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (U.S.)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (U.S.)

Aurobindo Pharma Limited (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF OVERACTIVE BLADDER DRUG**

- 1.1 Definition of Overactive Bladder Drug in This Report
- 1.2 Commercial Types of Overactive Bladder Drug
  - 1.2.1 Anticholinergics
  - 1.2.2 Solifenacin
  - 1.2.3 Oxybutynin
  - 1.2.4 Darifenacin
  - 1.2.5 Fesoterodine
  - 1.2.6 Tolterodine
  - 1.2.7 Trospium
  - 1.2.8 Others
- 1.3 Downstream Application of Overactive Bladder Drug
  - 1.3.1 Idiopathic Bladder Overactivity
  - 1.3.2 Neurogenic Bladder Overactivity
- 1.4 Development History of Overactive Bladder Drug
- 1.5 Market Status and Trend of Overactive Bladder Drug 2013-2023
  - 1.5.1 Global Overactive Bladder Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Overactive Bladder Drug Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Overactive Bladder Drug 2013-2017
- 2.2 Sales Market of Overactive Bladder Drug by Regions
  - 2.2.1 Sales Volume of Overactive Bladder Drug by Regions
  - 2.2.2 Sales Value of Overactive Bladder Drug by Regions
- 2.3 Production Market of Overactive Bladder Drug by Regions
- 2.4 Global Market Forecast of Overactive Bladder Drug 2018-2023
  - 2.4.1 Global Market Forecast of Overactive Bladder Drug 2018-2023
  - 2.4.2 Market Forecast of Overactive Bladder Drug by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Overactive Bladder Drug by Types
- 3.2 Sales Value of Overactive Bladder Drug by Types
- 3.3 Market Forecast of Overactive Bladder Drug by Types

## **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Overactive Bladder Drug by Downstream Industry
- 4.2 Global Market Forecast of Overactive Bladder Drug by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Overactive Bladder Drug Market Status by Countries
  - 5.1.1 North America Overactive Bladder Drug Sales by Countries (2013-2017)
  - 5.1.2 North America Overactive Bladder Drug Revenue by Countries (2013-2017)
  - 5.1.3 United States Overactive Bladder Drug Market Status (2013-2017)
  - 5.1.4 Canada Overactive Bladder Drug Market Status (2013-2017)
  - 5.1.5 Mexico Overactive Bladder Drug Market Status (2013-2017)
- 5.2 North America Overactive Bladder Drug Market Status by Manufacturers
- 5.3 North America Overactive Bladder Drug Market Status by Type (2013-2017)
  - 5.3.1 North America Overactive Bladder Drug Sales by Type (2013-2017)
  - 5.3.2 North America Overactive Bladder Drug Revenue by Type (2013-2017)
- 5.4 North America Overactive Bladder Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Overactive Bladder Drug Market Status by Countries
  - 6.1.1 Europe Overactive Bladder Drug Sales by Countries (2013-2017)
  - 6.1.2 Europe Overactive Bladder Drug Revenue by Countries (2013-2017)
  - 6.1.3 Germany Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.4 UK Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.5 France Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.6 Italy Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.7 Russia Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.8 Spain Overactive Bladder Drug Market Status (2013-2017)
  - 6.1.9 Benelux Overactive Bladder Drug Market Status (2013-2017)
- 6.2 Europe Overactive Bladder Drug Market Status by Manufacturers
- 6.3 Europe Overactive Bladder Drug Market Status by Type (2013-2017)
  - 6.3.1 Europe Overactive Bladder Drug Sales by Type (2013-2017)
  - 6.3.2 Europe Overactive Bladder Drug Revenue by Type (2013-2017)

6.4 Europe Overactive Bladder Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

7.1 Asia Pacific Overactive Bladder Drug Market Status by Countries

7.1.1 Asia Pacific Overactive Bladder Drug Sales by Countries (2013-2017)

7.1.2 Asia Pacific Overactive Bladder Drug Revenue by Countries (2013-2017)

7.1.3 China Overactive Bladder Drug Market Status (2013-2017)

7.1.4 Japan Overactive Bladder Drug Market Status (2013-2017)

7.1.5 India Overactive Bladder Drug Market Status (2013-2017)

7.1.6 Southeast Asia Overactive Bladder Drug Market Status (2013-2017)

7.1.7 Australia Overactive Bladder Drug Market Status (2013-2017)

7.2 Asia Pacific Overactive Bladder Drug Market Status by Manufacturers

7.3 Asia Pacific Overactive Bladder Drug Market Status by Type (2013-2017)

7.3.1 Asia Pacific Overactive Bladder Drug Sales by Type (2013-2017)

7.3.2 Asia Pacific Overactive Bladder Drug Revenue by Type (2013-2017)

7.4 Asia Pacific Overactive Bladder Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

8.1 Latin America Overactive Bladder Drug Market Status by Countries

8.1.1 Latin America Overactive Bladder Drug Sales by Countries (2013-2017)

8.1.2 Latin America Overactive Bladder Drug Revenue by Countries (2013-2017)

8.1.3 Brazil Overactive Bladder Drug Market Status (2013-2017)

8.1.4 Argentina Overactive Bladder Drug Market Status (2013-2017)

8.1.5 Colombia Overactive Bladder Drug Market Status (2013-2017)

8.2 Latin America Overactive Bladder Drug Market Status by Manufacturers

8.3 Latin America Overactive Bladder Drug Market Status by Type (2013-2017)

8.3.1 Latin America Overactive Bladder Drug Sales by Type (2013-2017)

8.3.2 Latin America Overactive Bladder Drug Revenue by Type (2013-2017)

8.4 Latin America Overactive Bladder Drug Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

## 9.1 Middle East and Africa Overactive Bladder Drug Market Status by Countries

9.1.1 Middle East and Africa Overactive Bladder Drug Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Overactive Bladder Drug Revenue by Countries (2013-2017)

9.1.3 Middle East Overactive Bladder Drug Market Status (2013-2017)

9.1.4 Africa Overactive Bladder Drug Market Status (2013-2017)

## 9.2 Middle East and Africa Overactive Bladder Drug Market Status by Manufacturers

## 9.3 Middle East and Africa Overactive Bladder Drug Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Overactive Bladder Drug Sales by Type (2013-2017)

9.3.2 Middle East and Africa Overactive Bladder Drug Revenue by Type (2013-2017)

## 9.4 Middle East and Africa Overactive Bladder Drug Market Status by Downstream Industry (2013-2017)

# **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF OVERACTIVE BLADDER DRUG**

## 10.1 Global Economy Situation and Trend Overview

## 10.2 Overactive Bladder Drug Downstream Industry Situation and Trend Overview

# **CHAPTER 11 OVERACTIVE BLADDER DRUG MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

## 11.1 Production Volume of Overactive Bladder Drug by Major Manufacturers

## 11.2 Production Value of Overactive Bladder Drug by Major Manufacturers

## 11.3 Basic Information of Overactive Bladder Drug by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Overactive Bladder Drug Major Manufacturer

11.3.2 Employees and Revenue Level of Overactive Bladder Drug Major Manufacturer

## 11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

# **CHAPTER 12 OVERACTIVE BLADDER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

## 12.1 Astellas Pharma, Inc. (Japan)

12.1.1 Company profile



- 12.1.2 Representative Overactive Bladder Drug Product
- 12.1.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Astellas Pharma, Inc. (Japan)
- 12.2 Pfizer, Inc. (U.S.)
  - 12.2.1 Company profile
  - 12.2.2 Representative Overactive Bladder Drug Product
  - 12.2.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Pfizer, Inc. (U.S.)
- 12.3 Teva Pharmaceutical Industries Limited (Israel)
  - 12.3.1 Company profile
  - 12.3.2 Representative Overactive Bladder Drug Product
  - 12.3.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited (Israel)
- 12.4 Allergan, Plc (Ireland)
  - 12.4.1 Company profile
  - 12.4.2 Representative Overactive Bladder Drug Product
  - 12.4.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Allergan, Plc (Ireland)
- 12.5 Medtronic plc (Ireland)
  - 12.5.1 Company profile
  - 12.5.2 Representative Overactive Bladder Drug Product
  - 12.5.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Medtronic plc (Ireland)
- 12.6 Mylan N.V. (U.S.)
  - 12.6.1 Company profile
  - 12.6.2 Representative Overactive Bladder Drug Product
  - 12.6.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Mylan N.V. (U.S.)
- 12.7 Endo International plc (Ireland)
  - 12.7.1 Company profile
  - 12.7.2 Representative Overactive Bladder Drug Product
  - 12.7.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Endo International plc (Ireland)
- 12.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
  - 12.8.1 Company profile
  - 12.8.2 Representative Overactive Bladder Drug Product
  - 12.8.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Hisamitsu Pharmaceutical Co., Inc. (Japan)
- 12.9 Sanofi (France)

- 12.9.1 Company profile
- 12.9.2 Representative Overactive Bladder Drug Product
- 12.9.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Sanofi (France)
- 12.10 Apotex, Inc. (Canada)
  - 12.10.1 Company profile
  - 12.10.2 Representative Overactive Bladder Drug Product
  - 12.10.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Apotex, Inc. (Canada)
- 12.11 Cogentix Medical, Inc. (U.S.)
  - 12.11.1 Company profile
  - 12.11.2 Representative Overactive Bladder Drug Product
  - 12.11.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Cogentix Medical, Inc. (U.S.)
- 12.12 Aurobindo Pharma Limited (India)
  - 12.12.1 Company profile
  - 12.12.2 Representative Overactive Bladder Drug Product
  - 12.12.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Aurobindo Pharma Limited (India)

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OVERACTIVE BLADDER DRUG**

- 13.1 Industry Chain of Overactive Bladder Drug
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF OVERACTIVE BLADDER DRUG**

- 14.1 Cost Structure Analysis of Overactive Bladder Drug
- 14.2 Raw Materials Cost Analysis of Overactive Bladder Drug
- 14.3 Labor Cost Analysis of Overactive Bladder Drug
- 14.4 Manufacturing Expenses Analysis of Overactive Bladder Drug

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**



## 16.1 Methodology/Research Approach

### 16.1.1 Research Programs/Design

### 16.1.2 Market Size Estimation

### 16.1.3 Market Breakdown and Data Triangulation

## 16.2 Data Source

### 16.2.1 Secondary Sources

### 16.2.2 Primary Sources

## 16.3 Reference

## I would like to order

Product name: Overactive Bladder Drug-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/O1D79C7A01AMEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O1D79C7A01AMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

